About this journal
Aims and scope
Breast Cancer: Targets and Therapy is an international, peer reviewed, open access journal focusing on breast cancer, basic and translational research, clinical trials and treatment. The latter includes outcome studies that incorporate preventative and integrated treatment strategies for enhanced survival, and quality of life for cancer patients.
Breast Cancer: Targets and Therapy will no longer consider meta-analyses for publication.
Specific topics covered in the journal include:
- Epidemiology, detection and screening
- Cellular research and biomarkers
- Cancer stem cells
- Cancer dormancy and metastasis
- Novel biotargets and other agents such as small non-coding RNA
- Drug Delivery Systems
- Optimal clinical use of existing anti-cancer agents, including combination therapies
- Radiation and surgery
- Palliative care
- Patient adherence, quality of life, satisfaction
- Health economic evaluations
The journal welcomes submitted papers covering original research articles, reviews, basic and translational research, clinical and epidemiological studies, treatment guidelines, expert opinion and commentaries.
Breast Cancer: Targets and Therapy will no longer consider case reports/series for publication.
When considering submission of a paper utilizing publicly available data (e.g. SEER/GWAS/TCGA/GEO etc.), authors should ensure that such studies add significantly to the body of knowledge about breast cancer or relevant phenotype and that they are validated using the authors’ own data through replication in an independent sample set and functional follow-up.
All papers submitted on or after 3 August 2022 must meet these requirements.
Journal metrics
Usage
- 103K annual downloads/views
Citation metrics
- 3.3 (2023) Impact Factor
- Q2 Impact Factor Best Quartile
- 4.2 (2023) 5 year IF
- 4.1 (2023) CiteScore (Scopus)
- 1.009 (2023) SNIP
- 0.933 (2023) SJR
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.
For more details, please read the Author Services guide to understanding journal metrics.
Journal metrics in brief
Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).
- Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.
Citation Metrics
- Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
- Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
- 5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
- CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
- CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
- SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
- SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.
Speed/acceptance
- From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
- From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
- From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
- Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.
For more details on the data above, please read the Author Services guide to understanding journal metrics.
*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus
Editorial board
Editor-in-Chief
Professor Pranela Rameshwar, Medicine-Hematology/Oncology, Rutgers New Jersey Medical School, United States
Dr. Pooja Advani, Assistant Professor of Medicine, Mayo Clinic
Associate Editors-in-Chief
Professor Robert Clarke, Cancer Systems Biology, The Hormel Institute, University of Minnesota, United States
Professor Harikrishna Nakshatri, Breast Cancer Research, Indiana University School of Medicine, United States
Editorial Board
Prof. Dr. Emmanuel Akporiaye, Chiles Research Institute, Providence Portland Cancer Center, United States
Professor Hamid Band, Center for Breast Cancer, University of Nebraska Medical Center, United States
Dr Abhijit De, Molecular Functional Imaging Laboratory, Advanced Centre of Teaching Research and Education in Cancer, Tata Memorial Centre, Mumbai, India
Dr Hesham Elghazaly, Clinical Oncology, Ain Shams University, Cairo, Egypt
Professor Ramesh Ganju, Pathology, Ohio State University, United States
Dr Pere Gascon, Laboratory of Molecular & Translational Oncology-CELLEX C, University of Barcelona, Spain
Dr Mark Greene, John Eckman Professor of Medical Sciences, Emeritus Professor of Pathology and Laboratory Medicine, Department of Pathology and Laboratory Medicine , Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
Professor Jun-Lin Guan, Cancer Biology, University of Cincinnati, United States
Professor Jennifer Hu, Public Health Sciences, University of Miller School of Medicine, United States
Professor Phillip Koeffler, Division of Hematology and Oncology, Cedars-Sinai Medical Center, University of California, Los Angeles, CA, United States
Professor Rong Li, Department of Biochemistry & Molecular Medicine, The George Washington University, United States
Professor Dan Liebermann, Medical Genetics & Molecular Biochemistry, Temple University, Philadelphia, United States
Dr James Andrew McCubrey, Microbiology & Immunology, East Carolina University, United States
Dr Kathleen McEnnis, Assistant Professor, Department of Chemical and Materials Engineering, New Jersey Institute of Technology (NJIT), USA
Dr George Nahas, University of Miami Health System, Miami, FL, United States
Dr Jimmy S. Patel,Emory Radiation Oncology PGY2, Emory Winship Cancer Institute, United States
Professor Ratna B. Ray, Pathology, Saint Louis University School of Medicine, United States
Professor Avraham Raz, Department of Pathology and Radiation Oncology, Wayne State University, Detroit, United States
Prof. Dr. Stephen Safe, Department of Veterinary Physiology and Pharmacology, Texas A&M University, United States
Professor Edward Schwartz, Albert Einstein College of Medicine, Bronx, NY, United States
Professor Lalita R. Shevde-Samant, Department of Pathology, University of Alabama at Birmingham, United States
Dr Seema Singh, Department of Pathology, University of South Alabama, Mitchell Cancer Institute, United States
Professor Guangchao Sui, College of Life Science, Northeast Forestry University, China Mainland (PRC)
Professor Jules Sumkin, Radiology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
Dr Debra Tonetti, Department of Biopharmaceutical Sciences, College of Pharmacy, Chicago, IL, United States
Dr Nykia Walker, University of Maryland, United States
Professor Dennis Watson, Laboratory Medicine, Medical University of South Carolina, United States
Professor Lily Yang, Department of Surgery, Emory University School of Medicine, United States
Professor Dihua Yu, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer, United States
Professor Howard Zaren, Lewis Cancer and Research Pavilion, at St. Joseph's/Candler Hospital System in Savannah, GA, United States
Professor Jian-Ting Zhang, Department of Cancer Biology, University of Toledo College of Medicine & Life Sciences, Ohio, United States
Abstracting and indexing
Breast Cancer: Targets and Therapy is indexed/tracked/covered by the following services:
Current Contents®/Clinical MedicineBiological Abstracts
BIOSIS Previews (Clarivate Analytics)
Directory of Open Access Journals (DOAJ)
EMBASE (Elsevier)
Journal Citation Reports/Science Edition
Medline (NLM)
Pubmed (NLM)
PubMed Central Selective Deposit Medicine & Health (NLM)
Science Citation Index Expanded (Clarivate Analytics)
Scopus (Elsevier)
Open access
Breast Cancer: Targets and Therapy is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
- Increase the discoverability and readership of your article
- Make an impact and reach new readers, not just those with easy access to a research library
- Freely share your work with anyone, anywhere
- Comply with funding mandates and meet the requirements of your institution, employer or funder
- Rigorous peer review for every open access article
Article Publishing Charges (APC)
To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.
Use our APC finder to calculate your article publishing charge
Continuous
Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site (link opens in a new window) Instructions for authors